KR850005826A - 1,4-디히드로-2,6-디메틸피리딘-3,5-디카르복실산의 비대칭 디에스테르의 제조방법 - Google Patents

1,4-디히드로-2,6-디메틸피리딘-3,5-디카르복실산의 비대칭 디에스테르의 제조방법 Download PDF

Info

Publication number
KR850005826A
KR850005826A KR1019850000888A KR850000888A KR850005826A KR 850005826 A KR850005826 A KR 850005826A KR 1019850000888 A KR1019850000888 A KR 1019850000888A KR 850000888 A KR850000888 A KR 850000888A KR 850005826 A KR850005826 A KR 850005826A
Authority
KR
South Korea
Prior art keywords
group
carbon atoms
formula
nitrophenyl
general formula
Prior art date
Application number
KR1019850000888A
Other languages
English (en)
Other versions
KR910005231B1 (ko
Inventor
나르디 단테 (외 3)
Original Assignee
람베르토 앙드레오띠
레코르다티 에스·에이, 케미칼 앤드 파마세티컬 컴페니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10556581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR850005826(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 람베르토 앙드레오띠, 레코르다티 에스·에이, 케미칼 앤드 파마세티컬 컴페니 filed Critical 람베르토 앙드레오띠
Publication of KR850005826A publication Critical patent/KR850005826A/ko
Application granted granted Critical
Publication of KR910005231B1 publication Critical patent/KR910005231B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

내용 없음

Description

1,4-디히드로-2,6-디메틸피리딘-3,5-디카르복실산의 비대칭 디에스테르의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 하기 일반식(Ⅱ)의 화합물을 하기 일반식(Ⅲ)의 화합물과 축합시키고, 축합된 하기 일반식(Ⅴ)의 화합물과 반응시켜 하기 일반식(Ⅵ)의 화합물을 수득한 후, A1이 일반식 AX의 기를 나타낼 때 이를 하기 일반식(Ⅳ)의 기로 전환시킴을 특징으로 하는 하기 일반식(Ⅰ)의 1,4-디히드로-2,6-디메틸피리딘-3,5-디카르복실산의 비대칭 디에스테르, 그의 입체 이성질체, 또는 약학적으로 수용할 수 있는 그의 산부가염의 제조방법.
    (상기 식중, Ph는 페닐기를 나타내고, Ar은 2-니트로페닐, 3-니트로페닐, 2,3-디클로로페닐 또는 벤조푸라잔-4-일기를 나타내며, A는 2∼6탄소원자를 함유한 직쇄 또는 측쇄 알킬렌기를 나타내고, R은 1∼6탄소원자를 갖는 알콕시기에 의해 임의 모노 치화된 1∼6탄소원자를 갖는 직쇄 또는 측쇄 알킬기를 나타내며, R1은 수소원자, 히드록시기 또는 1∼4탄소원자를 갖는 알킬기를 나타내고, R2는 수소원자 또는 메틸기를 나타내며, A1은 (a) 상기 일반식(Ⅳ)의 기 또는 (b) 일반식 AX의 기를 나타내고, X는 할로겐원자를 나타낸다.)
  2. 제1항에 있어서, A1이 일반식 AX의 기를 나타내며, AX의 기를 일반식(Ⅳ)의 기로 전환시키는 반응이 일반식(Ⅵ)의 화합물을 하기 일반식(Ⅶ)의 3,3-디페닐프로필아민 유도체와 반응시킴으로써 수행되는 방법.
    [화학식 7]
    (상기 식중, R1, R2및 Ph는 제1항에 정의한 바와 같다).
  3. 하기 일반식(Ⅵb)의 피리딘 유도체를 하기 일반식(Ⅶ)이 3,3-디페닐프로필아민 유도체와 축합시킴을 특징으로 하는 하기 일반식(Ⅰ)의 1,4-디히드로-2,6-디메틸피리딘-3,5-디카르복실산의 비대칭디에스테르, 그의 입체 이성질체, 또는 약학적으로 수용할 수 있는 그의 산부가염의 제조방법.
    (상기 식중, Ph는 페닐기를 나타내고, Ar은 2-니트로페닐, 3-니트로페닐, 2,3-디클로로페닐 또는 벤조푸라잔-4-일기를 나타내며, A는 2∼6 탄소원자를 함유한 직쇄 또는 측쇄알킬렌기를 나타내고, R은 1∼6탄소원자를 갖는 알콕시기에 의해 임의 모노 치환된 1∼6탄소원자를 갖는 직쇄 또는 측쇄알킬기를 나타내며, R1은 수소원자, 히드록시기 또는 1∼4탄소원자를 갖는 알킬기를 나타내고, R2는 수소원자 또는 메틸기를 나타내며, X는 할로겐원자를 나타낸다).
  4. 하기 일반식(Ⅸ)의 피리딘 유도체를 하기 일반식(Ⅷ)의 화합물과 축합시킴을 특징으로 하는 하기 일반식(Ⅰ)의 1,4-디히드로-2,6-디메틸피리딘-3,5-디카르복실산의 비대칭 디에스테르, 그의 입체 이성질체 또는 약학적으로 수용할 수 있는 그의 산부가염의 제조방법.
    (상기 식중, Ph는 페닐기를 나타내고, Ar은 2-니트로페닐, 3-니트로페닐, 2,3-디클로로페닐 또는 벤조푸라잔-4-일기를 나타내며, A는 2∼6탄소원자를 함유한 직쇄 또는 측쇄알킬렌기를 나타내고, R은 1∼6탄소원자를 갖는 알콕시기에 의해 염의 모노치환된 1∼6탄소원자를 갖는 직쇄 또는 측쇄알킬기를 나타내며, R1은 수소원자, 히드록시기 또는 1∼4탄소원자를 갖는 알킬기를 나타내고, R2는 수소원자 또는 메틸기를 나타내며, Z는 할로겐원자 또는 히드록시기를 나타낸다).
  5. 하기 일반식(Ⅸ)의 피리딘 유도체를 일반식 YAX의 화합물과 축합시키고, 축합물을 하기 일반식(Ⅶ)의 3,3-디페닐프로필아민 유도체와 더축합 시킴을 특징으로 하는 하기 일반식(Ⅰ)의 1,4-디히드로-2,6-디메틸피리딘-,5-디카르복실산의 비대칭 디에스테르, 그의 입성이성질체 또는 약학적으로 수용할 수 있는 그의 산부가염의 제조방법.
    (상기 식중, Ph는 페닐기를 나타내고, Ar은 2-니트로페닐, 3-니트로페닐, 2,3-디클로로페닐 또는 벤조푸라잔-4-일기를 나타내며, A는 2∼6탄소원자를 함유한 직쇄 또는 측쇄알킬렌기를 나타내고, R은 1~6탄소원자를 갖는 알콕시기에 의해 임의 모노 치환된 1~6탄소원자를 갖는 직쇄 또는 측쇄알킬기를 나타내며, R1은 수소원자, 히드록시기 또는 1∼4탄소원자를 갖는 알킬기를 나타내고, R2는 수소원자 또는 메틸기를 나타내며, X 및 Y는 할로겐원자를 나타낸다).
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850000888A 1984-02-14 1985-02-13 1,4-디히드로-2,6-디메틸피리딘-3,5-디카르복실산의 비대칭 디에스테르의 제조방법 KR910005231B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8403866 1984-02-14
GB3866 1984-02-14
GB848403866A GB8403866D0 (en) 1984-02-14 1984-02-14 Diphenylalkylaminoalkyl esters

Publications (2)

Publication Number Publication Date
KR850005826A true KR850005826A (ko) 1985-09-26
KR910005231B1 KR910005231B1 (ko) 1991-07-24

Family

ID=10556581

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850000888A KR910005231B1 (ko) 1984-02-14 1985-02-13 1,4-디히드로-2,6-디메틸피리딘-3,5-디카르복실산의 비대칭 디에스테르의 제조방법

Country Status (29)

Country Link
US (3) US4705797A (ko)
EP (1) EP0153016B1 (ko)
JP (1) JPS60199874A (ko)
KR (1) KR910005231B1 (ko)
AR (1) AR240804A1 (ko)
AT (1) ATE52772T1 (ko)
AU (1) AU570534B2 (ko)
BR (1) BR1101167A (ko)
CA (1) CA1277666C (ko)
DE (2) DE3577703D1 (ko)
DK (1) DK160985C (ko)
DZ (1) DZ748A1 (ko)
EG (1) EG17772A (ko)
ES (1) ES8602664A1 (ko)
FI (1) FI83954C (ko)
GB (1) GB8403866D0 (ko)
GR (1) GR850363B (ko)
HU (1) HU194171B (ko)
IE (1) IE57715B1 (ko)
IL (1) IL74238A (ko)
LU (1) LU90069I2 (ko)
MX (1) MX156874A (ko)
NL (1) NL970025I2 (ko)
NO (2) NO166123C (ko)
NZ (1) NZ210866A (ko)
PH (1) PH20725A (ko)
PT (1) PT79963B (ko)
SG (1) SG48590G (ko)
ZA (1) ZA85656B (ko)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561213B2 (en) * 1983-06-02 1987-04-30 Teijin Limited 1, 4-dihydropyridine derivative
US4994476A (en) * 1984-10-31 1991-02-19 Bristol-Myers Company Dihydropyridin-3,5-dicarboxylates incorporating aryloxypropanolamine moieties
DE3677319D1 (de) * 1985-10-22 1991-03-07 Sanwa Kagaku Kenkyusho Co Pharmazeutische 1,4-dihydropyridinderivate, ihre salze und herstellung.
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
JPH02149563A (ja) * 1988-11-30 1990-06-08 Nisshin Flour Milling Co Ltd ２−ハロエトキシカルボニル基を含有する１，４−ジヒドロピリジン誘導体の製造法
IT1279529B1 (it) * 1995-05-12 1997-12-16 Recordati Chem Pharm Procedimento di preparazione ed uso degli enantiomeri (s) di derivati 1,4-diidropiridinici per il trattamento dell'insufficienza cardiaca
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5912351A (en) * 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
IT1274480B (it) * 1995-05-12 1997-07-17 Recordati Chem Pharm Procedimento migliorato per la preparazione della lercanidipina cloridrato
US5851636A (en) * 1995-12-29 1998-12-22 Lantec Products, Inc. Ceramic packing with channels for thermal and catalytic beds
ITMI20011727A1 (it) * 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
ITMI20011726A1 (it) * 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
GEP20074134B (en) 2002-08-19 2007-06-25 Pfizer Prod Inc Combination therapy for hyperproliferative diseases
US20040147566A1 (en) * 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
US20050101640A1 (en) * 2002-10-16 2005-05-12 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
NZ543741A (en) 2003-05-30 2009-10-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors
WO2005107374A2 (en) * 2004-05-07 2005-11-17 Sun Pharmaceutical Industries Limited A process for the preparation of 1,4-dihydropyridine-3,5-dicarboxylic acid derivative
RU2007106714A (ru) * 2004-07-26 2008-09-10 Байер Шеринг Фарма Аг (De) Лечение легочной гипертензии путем ингаляции илопростата с препаратом микрочастиц
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
US20060134212A1 (en) * 2004-09-02 2006-06-22 Forest Laboratories, Inc. Lercanidipine immediate release compositions
US20060165788A1 (en) * 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
KR100616276B1 (ko) * 2004-09-21 2006-08-28 일동제약주식회사 2,엔-디메틸-엔-(3,3-디페닐프로필)-1-아미노-2-프로판올의제조방법
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
KR100651212B1 (ko) 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
IL165525A0 (en) * 2004-12-02 2006-01-15 Motivan Ltd Intermediates and a process for the manufacturing for antihypertensive dihydropyridine derivative suitable for pharmaceutical compositions
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
KR100638171B1 (ko) * 2005-03-25 2006-10-26 건일제약 주식회사 2,ｎ-디메틸-ｎ-(3,3-디페닐프로필)-1-아미노-2-프로판올의제조방법
ATE445602T1 (de) * 2005-06-15 2009-10-15 Hetero Drugs Ltd Neues verfahren zur herstellung von lercanidipin
RU2425033C2 (ru) 2005-09-16 2011-07-27 Гленмарк Фармасьютикалз Лимитед Полиморфная форма гидрохлорида лерканидипина и способ ее получения
WO2007054969A2 (en) * 2005-09-21 2007-05-18 Torrent Pharmaceuticals Limited Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2111863B1 (en) 2005-10-26 2012-03-28 Asahi Kasei Pharma Corporation Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension
US8026377B2 (en) 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2007120135A1 (en) * 2006-04-17 2007-10-25 Forest Laboratories, Inc. Lercanidipine immediate release composition
EP1860102B1 (en) * 2006-05-24 2008-11-26 CF Pharma Ltd. Process for Producing Lercanidipine
WO2008015248A1 (en) * 2006-08-04 2008-02-07 Recordati Ireland Limited Process for preparing amorphous lercanidipine hydrochloride
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
US20110040097A1 (en) * 2006-12-29 2011-02-17 Dongwoo Syntech Co., Ltd Process for preparing lercanidipine hydrochloride
KR100848935B1 (ko) 2007-05-16 2008-07-29 주식회사 대희화학 생체 촉매 효소를 이용한 광학 선택적 가수분해방법
SI2585051T2 (sl) 2010-06-23 2020-07-31 Krka, D.D., Novo Mesto Farmacevtske oralne odmerne oblike,ki obsegajo lerkanidipin in enalapril in njune farmacevtsko sprejemljive soli
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
EP2444394A1 (en) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Process for the preparation of amorphous form of lercanidipine HCI
WO2012085249A2 (en) 2010-12-24 2012-06-28 Krka, D.D., Novo Mesto Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts
WO2012123966A1 (en) 2011-03-04 2012-09-20 Arch Pharmalabs Limited Process for the preparation of 4 -substituted -1, 4-dihydropyridines
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985758A (en) * 1973-02-20 1976-10-12 Yamanouchi Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives
JPS5762257A (en) * 1980-10-03 1982-04-15 Yoshitomi Pharmaceut Ind Ltd 1,4-dihydropyridine-3,5-dicarboxylic acid ester or its salt
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
EP0080220B1 (en) * 1981-11-17 1986-02-19 FISONS plc Dihydropyridines, methods for their production and their formulation and use as pharmaceuticals
EP0094159B1 (en) * 1982-05-10 1990-03-14 Takeda Chemical Industries, Ltd. Dihydropyridine derivatives, their production and use
AU561213B2 (en) * 1983-06-02 1987-04-30 Teijin Limited 1, 4-dihydropyridine derivative
NO854021L (no) * 1984-10-26 1986-04-28 Bayer Ag 1,4-dihydropyridin-hydroksyaminer og fremgangsmaate til fremstilling derav.
GB8503424D0 (en) * 1985-02-11 1985-03-13 Ici Plc Heterocyclic derivatives

Also Published As

Publication number Publication date
ES540385A0 (es) 1985-11-16
NL970025I2 (nl) 1998-01-05
AU3868985A (en) 1985-09-12
HUT37399A (en) 1985-12-28
FI83954B (fi) 1991-06-14
EP0153016A3 (en) 1985-10-02
PH20725A (en) 1987-03-30
AR240804A2 (es) 1991-02-28
IE850280L (en) 1985-08-14
JPS60199874A (ja) 1985-10-09
NL970025I1 (nl) 1997-09-01
PT79963A (en) 1985-03-01
DK160985C (da) 1991-11-04
BR1101167A (pt) 2004-08-17
DZ748A1 (fr) 2004-09-13
NO166123B (no) 1991-02-25
NZ210866A (en) 1988-07-28
SG48590G (en) 1990-08-17
LU90069I2 (fr) 1997-07-23
DE10199007I2 (de) 2003-01-09
IE57715B1 (en) 1993-03-10
ES8602664A1 (es) 1985-11-16
NO850521L (no) 1985-08-15
EG17772A (en) 1991-08-30
GR850363B (ko) 1986-02-06
ATE52772T1 (de) 1990-06-15
IL74238A (en) 1988-07-31
HU194171B (en) 1988-01-28
EP0153016A2 (en) 1985-08-28
DK63085A (da) 1985-08-15
IL74238A0 (en) 1985-05-31
FI850535L (fi) 1985-08-15
ZA85656B (en) 1985-08-28
CA1277666C (en) 1990-12-11
DE10199007I1 (de) 2001-04-12
PT79963B (en) 1986-11-10
GB8403866D0 (en) 1984-03-21
US4705797A (en) 1987-11-10
NO2000011I1 (no) 2000-10-17
US4968832A (en) 1990-11-06
AR240804A1 (es) 1991-02-28
US4772621A (en) 1988-09-20
DE3577703D1 (de) 1990-06-21
FI83954C (fi) 1991-09-25
MX156874A (es) 1988-10-08
EP0153016B1 (en) 1990-05-16
KR910005231B1 (ko) 1991-07-24
NO166123C (no) 1991-06-05
AU570534B2 (en) 1988-03-17
JPH0517908B2 (ko) 1993-03-10
DK63085D0 (da) 1985-02-12
FI850535A0 (fi) 1985-02-08
DK160985B (da) 1991-05-13

Similar Documents

Publication Publication Date Title
KR850005826A (ko) 1,4-디히드로-2,6-디메틸피리딘-3,5-디카르복실산의 비대칭 디에스테르의 제조방법
KR830007685A (ko) 세팔로스포린 유도체의 제조방법
KR830010060A (ko) 술포네이트 유도체의 제조법
KR880002823A (ko) 약제학적 화합물
KR850001905A (ko) 벤조시클로 알칸 유도체의 제조방법
KR840000534A (ko) 디히드로피리딘 화합물류의 제조방법
KR830005090A (ko) 3,7,11,15-테트라메틸-2,4,6,10,14-헥사데카펜타엔 산(酸)
KR930701419A (ko) 예정된 대칭성을 갖는 킬레이트제 제조를 위한 중간체 및 그의 제조 방법
KR890005128A (ko) 유기금속-함유 화합물
KR860002450A (ko) 아미노-알콜유도체의 제조방법
KR840005122A (ko) 메틸플라본 유도체의 제조방법
KR840000521A (ko) 3-메틸플라본-8-카르복실산 에스테르류의 제조방법
KR890006620A (ko) 퀴놀린 유도체 및 그의 제조법
KR860001102A (ko) 디히드로오로트산 유도체의 제조방법
KR860004051A (ko) 치환된 페닐피페라진 유도체의 제조방법
KR830005122A (ko) 1-아릴옥시-3-알킬아미노-2-프로판올류의 제조방법
KR850006004A (ko) [(1,3-디 옥소-1,3-프로판디일)디이미노)]비스벤 조산 유도체의 제조방법
KR850008155A (ko) 1,4-디히드로-2,6-디메틸-3-(알콕시카르보닐 또는 알콕시알콕시카르보닐)-4-(치환된 페닐)-피리딘-5-카르복실산의 에스테르의 제조방법
KR840001154A (ko) 1,2-디티올-3-일리덴 암모늄 유도체의 제조방법
KR850007247A (ko) 바이페닐릴설포닐 우레아의 제조방법
KR830010051A (ko) N-치환된 아미노산의 2-메톡시퍼닐에스 테르의 제조방법
KR870002118A (ko) 벤질아민 유도체 및 그 제조방법
KR860003224A (ko) N-벤조일 페닐 우레아의 제조방법
KR860003251A (ko) 에르골린 유도체의 제조방법
KR850006927A (ko) 4-아미노-테트라히드로-2-나프토산 유도체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040514

Year of fee payment: 14

EXPY Expiration of term